Search Results - "plasma half life"

Refine Results
  1. 1
  2. 2
  3. 3

    Subject Terms: ψ–Hamzah model, pancreatic ductal adenocarcinoma, PDAC therapy, pancreatic cancer stem cells, CSC targeting, tumor microenvironment modeling, KRAS G12D mutation therapy, TP53 mutation pathways, TGF-β signaling alteration, fibroblast-rich stroma resistance, tumor heterogeneity, metastasis modeling, fractional calculus in oncology, Caputo derivative in tumor modeling, fractional-order pharmacokinetics, fractal tumor geometry, chaotic immune–tumor interaction, non-linear cancer dynamics, Gompertz model limitations, logistic tumor model, immune suppression modeling, tumor–immune tensor field, stromal–vascular microenvironment, cancer stem cell relapse, tumor recurrence prevention, drug resistance modeling, nanovaccine design, MUC1-Tn glycopeptide antigen, KRAS^G12D mutant epitope vaccine, mesothelin peptide vaccine, CpG ODN adjuvant, MPLA adjuvant durability, PLGA nanoparticle carriers, w/o/w double emulsion method, nanoparticle encapsulation efficiency, nanoparticle zeta potential, DLS particle size analysis, immune durability T-cell response, IgG antibody formation, systemic immunological memory, vaccine stability, injection-site inflammation, absence of anaphylaxis, apoptosis induction in CSCs, tumor inhibition percentages, long-term immune durability, nano-liposomal drug delivery, Hamzah-CSC Inhibitor (HCI-1), Wnt/β-catenin pathway inhibition, GAPDH metabolic blocking, glucose depletion therapy, NAD⁺ metabolism suppression, nicotinamide mononucleotide (NMN), PEGylated liposomal carriers, liposomal encapsulation process, liposomal pharmacokinetics, plasma half-life measurement, ECM penetration efficiency, CD133+ CSC marker targeting, biliary clearance safety, liposomal drug stability, lyophilization preservation, CSC apoptosis assays, Panc-1 CSC+ experimental validation, Annexin-V apoptosis measurement, IFN-γ secretion, IL-2 immune stimulation, cytokine release safety, multi-compartment PK models, fractional pharmacodynamics, Grünwald–Letnikov derivative, variable-order fractional calculus, chaotic tumor modeling, non-deterministic drug distribution, receptor binding kinetics, Michaelis–Menten clearance pathways, immune checkpoint resistance, immune feedback oscillations, tumor hypoxia modeling, fibrotic pressure dynamics, angiogenesis suppression, metastatic pattern remapping, fractal immune simulation, tensorial tumor analysis, fractional fractal immune stimulation, computational oncology, systems pharmacology, bioinformatics integration, pharmacogenomic modeling, in silico cancer modeling, mathematical oncology frameworks, tumor–drug–immunity integration, adaptive CSC modeling, chaos-stability tumor modeling, immune escape prevention, apoptosis without recurrence, nano-vaccine industrial synthesis, multiphase microfluidic bioreactors, PDMS anti-adhesive coating, laminar–chaotic convection control, precision nitrogen/oxygen gas flow, thermal loop heating, fractal-chaotic order ψ parameterization, CSC protein fractional derivative modeling, nanoparticle antigen conjugation, gold nanoparticle vaccines, maleimide–thiol chemical conjugation, antigen attachment conditions, storage stability in low RH, ultrafiltration nanoparticle purification, industrial scale-up protocols, pharmacological safety standards, EMA/FDA fast-track potential, WHO therapeutic guidelines, legal intellectual property protection, Creative Commons licensing, Zenodo registration, ScienceOpen registration, ORCID author profile, patient-specific tumor modeling, personalized oncology approaches, computational immunology, nanomedicine engineering, regenerative oncology, mathematical immune system modeling, chaos-driven tumor suppression, fractional memory-driven pharmacology, spatiotemporal tumor simulations, computational biophysics, immune checkpoint integration, advanced drug design, targeted immunotherapy, bioengineering cancer therapies, nanobiological oncology, therapeutic innovation pathways, oncological chaos modeling, CSC eradication without relapse, systemic immune activation, integrated therapy frameworks, vaccine–drug dual therapy, resistant PDAC solutions, multi-scale therapeutic optimization, quantum-inspired cancer modeling, fractal nanomedicine design, adaptive therapeutic dynamics, clinical translation of fractional models, chaos-based drug design, tumor eradication predictions, resistant pancreatic cancer cure strategies, apoptosis-driven remission, mathematical proof-of-concept oncology, high-fidelity simulation frameworks, long-term CSC suppression, translational oncology research, precision medicine in PDAC, computational chaos-based pharmacology, CSC relapse prevention, nanocarrier engineering, immune cell infiltration modeling, lymphocyte activation mapping, macrophage modulation, Treg suppression modeling, fractal dimension tumor pathways, CSC metabolic adaptability, apoptosis probability modeling, CSC niche targeting, fibroblast suppression, matrix remodeling therapy, tumor vascular normalization, PDAC drug synergy, pharmacological fractal engineering, experimental nanomedicine validation, chaotic immune response synchronization, CSC elimination strategies, biocompatible therapeutic systems, advanced oncology simulation, fractional systems biology, CSC resilience dismantling, universal ψ–Hamzah cancer framework

  4. 4
  5. 5
  6. 6
  7. 7

    Source: Environmental health perspectives. 119(1)

    Subject Terms: Adult, Aged, Caprylates: analysis, blood, Environmental Exposure: analysis, statistics & numerical data, Environmental Monitoring, Female, Fluorocarbons: analysis, blood, Half-Life, Humans, Male, Middle Aged, Models, Biological, Ohio, Questionnaires, Residence Characteristics: statistics & numerical data, Water Pollutants, Chemical: analysis, blood, Water Supply: analysis, West Virginia, Young Adult, C8, Half-life, Pfa, Pfoa, Serum levels, Water contaminationperfluorooctanoic acid, adult, article, bioaccumulation, blood level, concentration (parameters), environmental exposure, female, human, male, plasma clearance, plasma half life, pollution monitoring, priority journal, residential area, United States, water contamination, Adult, Aged, Environmental Exposure, Environmental Monitoring, Female, Fluorocarbons, Half-Life, Humans, Male, Middle Aged, Models, Biological, Octanoic Acids, Ohio, Questionnaires, Residence Characteristics, Water Pollutants, Chemical, Water Supply, West Virginia, Young Adult, Adult, Aged, Caprylates: analysis, blood, Environmental Exposure: analysis, statistics & numerical data, Environmental Monitoring, Female, Fluorocarbons: analysis, blood, Half-Life, Humans, Male, Middle Aged, Models, Biological, Ohio, Questionnaires, Residence Characteristics: statistics & numerical data, Water Pollutants, Chemical: analysis, blood, Water Supply: analysis, West Virginia, Young Adult, C8, Half-life, Pfa, Pfoa, Serum levels, Water contaminationperfluorooctanoic acid, adult, article, bioaccumulation, blood level, concentration (parameters), environmental exposure, female, human, male, plasma clearance, plasma half life, pollution monitoring, priority journal, residential area, United States, water contamination, Adult, Aged, Environmental Exposure, Environmental Monitoring, Female, Fluorocarbons, Half-Life, Humans, Male, Middle Aged, Models, Biological, Octanoic Acids, Ohio, Questionnaires, Residence Characteristics, Water Pollutants, Chemical, Water Supply, West Virginia, Young Adult

    File Description: application/pdf

  8. 8

    Source: Nanomedicine: Nanotechnology, Biology and Medicine. 18:169-178

  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Source: Front Pharmacol
    Frontiers in Pharmacology, Vol 10 (2019)

    File Description: application/pdf

  15. 15
  16. 16
  17. 17

    Authors: An, G. Murry, D.J. Gajurel, K. et al.

    Source: Antimicrobial Agents and Chemotherapy. 63

    Subject Terms: Male, double blind procedure, drug safety, ultra performance liquid chromatography, limit of quantitation, phase 1 clinical trial, Clinical pharmacokinetics, diarrhea, Administration, Oral, volume of distribution, 0302 clinical medicine, aspartate aminotransferase, Anthelmintic agent, drug dose regimen, adult, single drug dose, Middle Aged, Healthy Volunteers, sore throat, unclassified drug, 3. Good health, female, leukocytosis, priority journal, oxfendazole glucuronide, Female, First-in-human study, eosinophilia, bicarbonate blood level, Half-Life, Adult, oxfendazole, drug exposure, pharmacokinetic parameters, side effect, Adolescent, area under the curve, Biological Availability, bicarbonate, urinary excretion, oxfendazole sulfate, Article, Young Adult, 03 medical and health sciences, male, Double-Blind Method, first in human study, activated partial thromboplastin time, neutropenia, no-observed-adverse-effect level, Humans, controlled study, human, normal human, arthralgia, Oxfendazole, fenbendazole, liquid chromatography-mass spectrometry, elimination half-life, viral gastroenteritis, Dose-Response Relationship, Drug, Cysticercosis, maximum plasma concentration, oxfendazole sulfone, leukopenia, drug bioavailability, renal clearance, major clinical study, drug metabolism, flatulence, plasma half life, intestine absorption, time to maximum plasma concentration, elimination rate constant, randomized controlled trial, drug solubility, PR interval, drug metabolite, Benzimidazoles, drug dose escalation, drug tolerability, plasma concentration-time curve

  18. 18
  19. 19
  20. 20